Have a feature idea you'd love to see implemented?
Let us know!
NVNO enVVeno Medical Corp
Price (delayed)
$3.44
Market cap
$45.86M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.39
Enterprise value
$44.71M
Hancock Jaffe Laboratories specializes in developing and manufacturing bioprosthetic (tissue-based) medical devices to establish improved standards of care for treating cardiac and vascular diseases. HJLI currently has two lead product
Highlights
The EPS has grown by 38% year-on-year and by 16% since the previous quarter
NVNO's debt is down by 21% YoY and by 6% from the previous quarter
NVNO's quick ratio has soared by 60% YoY but it is down by 20% QoQ
The equity rose by 33% year-on-year but it has declined by 9% since the previous quarter
Key stats
What are the main financial stats of NVNO
Market
Valuations
Earnings
Shares outstanding
13.33M
Market cap
$45.86M
Enterprise value
$44.71M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.19
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$20.6M
EBITDA
-$20.05M
Free cash flow
-$16.67M
Per share
Balance sheet
Liquidity
EPS
-$1.39
Free cash flow per share
-$1.04
Book value per share
$2.88
Revenue per share
$0
TBVPS
$2.55
Total assets
$41M
Total liabilities
$2.58M
Debt
$1.23M
Equity
$38.42M
Working capital
$37.84M
Debt to equity
0.03
Current ratio
23.33
Quick ratio
23.05
Net debt/EBITDA
0.06
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-50.7%
Return on equity
-54.2%
Return on invested capital
-55.6%
Return on capital employed
-52.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NVNO stock price
How has the enVVeno Medical stock price performed over time
Intraday
3.93%
1 week
4.88%
1 month
-23.56%
1 year
-34.48%
YTD
-33.07%
QTD
2.38%
Financial performance
How have enVVeno Medical's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$22.58M
Net income
-$20.6M
Gross margin
N/A
Net margin
N/A
enVVeno Medical's net income has increased by 18% YoY and by 7% from the previous quarter
enVVeno Medical's operating income has increased by 14% YoY and by 6% QoQ
Growth
What is enVVeno Medical's growth rate over time
Valuation
What is enVVeno Medical stock price valuation
P/E
N/A
P/B
1.19
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 38% year-on-year and by 16% since the previous quarter
The price to book (P/B) is 64% lower than the 5-year quarterly average of 3.3 and 34% lower than the last 4 quarters average of 1.8
The equity rose by 33% year-on-year but it has declined by 9% since the previous quarter
Efficiency
How efficient is enVVeno Medical business performance
NVNO's ROE is up by 22% year-on-year and by 13% since the previous quarter
The ROIC has grown by 21% YoY and by 14% from the previous quarter
The company's return on assets rose by 21% YoY and by 12% QoQ
Dividends
What is NVNO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NVNO.
Financial health
How did enVVeno Medical financials performed over time
enVVeno Medical's current ratio has soared by 60% YoY but it has decreased by 20% from the previous quarter
NVNO's quick ratio has soared by 60% YoY but it is down by 20% QoQ
NVNO's debt is 97% less than its equity
The company's debt to equity fell by 40% YoY
The equity rose by 33% year-on-year but it has declined by 9% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.